ATE232730T1 - Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten - Google Patents

Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten

Info

Publication number
ATE232730T1
ATE232730T1 AT92918977T AT92918977T ATE232730T1 AT E232730 T1 ATE232730 T1 AT E232730T1 AT 92918977 T AT92918977 T AT 92918977T AT 92918977 T AT92918977 T AT 92918977T AT E232730 T1 ATE232730 T1 AT E232730T1
Authority
AT
Austria
Prior art keywords
recipient
compositions
methods
mediated rejection
xenoantigens
Prior art date
Application number
AT92918977T
Other languages
English (en)
Inventor
A Heather Good
David K C Cooper
Andrew J Malcolm
Original Assignee
Alberta Res Council
Integris Baptist Med Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alberta Res Council, Integris Baptist Med Center Inc filed Critical Alberta Res Council
Application granted granted Critical
Publication of ATE232730T1 publication Critical patent/ATE232730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92918977T 1991-08-23 1992-08-21 Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten ATE232730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74952991A 1991-08-23 1991-08-23
PCT/US1992/007071 WO1993003735A1 (en) 1991-08-23 1992-08-21 Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients

Publications (1)

Publication Number Publication Date
ATE232730T1 true ATE232730T1 (de) 2003-03-15

Family

ID=25014128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92918977T ATE232730T1 (de) 1991-08-23 1992-08-21 Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten

Country Status (8)

Country Link
US (4) US5651968A (de)
EP (1) EP0661980B1 (de)
JP (1) JP3201523B2 (de)
AT (1) ATE232730T1 (de)
AU (1) AU666128B2 (de)
DE (1) DE69232928D1 (de)
IL (1) IL102916A (de)
WO (1) WO1993003735A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759763A4 (de) * 1994-05-13 1997-07-30 Baxter Int Vermeidung der hyperakuten abstossung von organtransplantaten von schwein zum primaten
US5785966A (en) * 1994-06-15 1998-07-28 Coles; John G. Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients
US20040047865A1 (en) * 1995-08-31 2004-03-11 Warner Richard Gareth Compositions and their uses
EP0775493A3 (de) * 1995-11-22 1998-08-12 Baxter International Inc. Extrakorporeale xenogene Organperfusion nach Antikörper-Verringerung durch Immunoapherese
AU1404597A (en) * 1995-12-21 1997-07-17 Procur Ab Galactopyranosides and their use
US7014049B2 (en) 1996-12-23 2006-03-21 Glycorex Transplantation Ab Device for bio-affinity material
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
ES2268776T3 (es) 1997-04-18 2007-03-16 Novartis Ag Neoglicoproteinas.
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
CA2326618A1 (en) 1998-04-15 1999-10-21 Baxter International Inc. Inhibition of xenoreactive antibodies
US6214901B1 (en) * 1998-04-27 2001-04-10 Surmodics, Inc. Bioactive agent release coating
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US20050265996A1 (en) * 2004-04-30 2005-12-01 Biopheresis Technologies, Inc. Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
WO2000033887A2 (en) * 1998-12-08 2000-06-15 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
AU2408700A (en) * 1999-01-11 2000-08-01 Baxter International Inc. Method and apparatus for selectively removing xenoreactive antibodies from blood, serum or plasma
ATE474590T1 (de) * 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US20040058888A1 (en) * 2000-01-13 2004-03-25 Laurent Bornaghi Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides
ES2304378T3 (es) * 2000-02-08 2008-10-16 Glycorex Transplantation Ab Soportes oligosacaridos para por ejemplo retirar anticuerpos de la sangre.
DE10036742A1 (de) * 2000-07-27 2002-02-21 Aesku Lab Diagnostika Vorrichtung zur Behandlung von Immunerkrankungen
FI20011403A7 (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US7541048B2 (en) 2004-04-06 2009-06-02 Surmodics, Inc. Coating compositions for bioactive agents
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US9045516B2 (en) * 2007-04-16 2015-06-02 Suri Saranathan Iyer Synthetic ligands for the differentiation of closely related toxins and pathogens
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
EP2698636A1 (de) 2012-08-13 2014-02-19 Fundació Institut d'Investigació Biomèdica de Bellvitge Verfahren und Reagenzien zur Vorbeugung und/oder Behandlung von Transplantatabstoßung
US10086054B2 (en) * 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
SG11201607484RA (en) 2014-03-13 2016-10-28 Univ Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
CA2996073A1 (en) 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
CN110699328B (zh) * 2019-08-21 2022-07-19 山东省滨州畜牧兽医研究院 一种b型猪肠道病毒及其应用
CN114920788B (zh) * 2022-05-30 2024-07-30 天津科技大学 人乳三糖半乳糖基乳糖的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5240601A (en) * 1988-11-09 1993-08-31 Chembiomed, Ltd. Affinity supports for hemoperfusion
US5149425A (en) * 1988-11-09 1992-09-22 Chembiomed, Ltd. Affinity supports for hemoperfusion

Also Published As

Publication number Publication date
EP0661980B1 (de) 2003-02-19
IL102916A (en) 1999-03-12
EP0661980A1 (de) 1995-07-12
AU666128B2 (en) 1996-02-01
US6607723B1 (en) 2003-08-19
WO1993003735A1 (en) 1993-03-04
EP0661980A4 (de) 1994-11-24
AU2505992A (en) 1993-03-16
US5695759A (en) 1997-12-09
JP3201523B2 (ja) 2001-08-20
IL102916A0 (en) 1993-01-31
JPH07501237A (ja) 1995-02-09
DE69232928D1 (de) 2003-03-27
US5767093A (en) 1998-06-16
US5651968A (en) 1997-07-29

Similar Documents

Publication Publication Date Title
ATE232730T1 (de) Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten
Kamada Experimental liver transplantation
Lexer et al. Hyperacute rejection in a discordant (pig to baboon) cardiac xenograft model
DE60235928D1 (de) Mittel zur Suppression von Transplantat-Abstossung
AU679437B2 (en) Induced tolerance to xenografts
DE3587266D1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
MXPA98002434A (es) Animales transgenicos para xenotrasplante con rechazo reducido de anticuerpos mediados.
ES2121788T3 (es) Anticuerpos dirigidos contra cd3.
DE69330566D1 (de) Steigerung der transplantattoleranz durch schwein cytokine
EP0700297A4 (de) Die erzeugung von toleranz gegen fremdtransplantaten durch tolerogenese mit hilfe von ersatzlebewesen
Linn et al. Renal xenograft prolongation by suppression of natural antibody
Cosyns et al. De novo membranous nephropathy in human renal allografts: Report of nine patients
Aksentijevich et al. Natural antibodies against bone marrow cells of a concordant xenogeneic species
WO1996032137B1 (en) Methods of inducing immune tolerance using immunotoxins
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
CA2116138A1 (en) Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
Ross et al. Parathyroid transplantation: fate of a long-term allograft in man
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
EP0959899A4 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
Bennet et al. A new in vitro model for the study of pig‐to‐human vascular hyperacute rejection
Leventhal et al. Xenotransplantation in rodents: A review and reclassification
Kemp Experimental xenotransplantation between distantly related nonprimate species
Dunning et al. A comparison of the performance of pig hearts perfused or human blood using an ex-vivo working heart model
CA2161349A1 (en) Immunoglobulin infusion in xenotransplantation
FR2669539B1 (fr) Dispositif pour la circulation artificielle du sang et transfuseur autologue de sang total.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties